Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04650399
Other study ID # VLA1553-321
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 31, 2022
Est. completion date February 15, 2024

Study information

Verified date May 2024
Source Butantan Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control will be administered as single immunization on Day 1. Overall, approximately 750 male and female subjects aged 12 years to <18 years will be enrolled into the study.


Description:

This is a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study comprising approximately 750 subjects aged 12 years to <18 years randomized in a 2:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The final dose of lyophilized VLA1553 or placebo will be administered as a single intramuscular immunization. Subjects in this study will be stratified by baseline serostatus. The primary objective of the study is to evaluate the immunogenicity and safety of the adult dose of VLA1553 28 days following the single immunization. Immunogenicity evaluations in the immunogenicity subset will include the proportion of subjects with seroprotective neutralizing CHIKV antibody titers above a surrogate threshold indicative of protection. The surrogate of protection reasonably likely to predict clinical benefit has been established in non-human primate passive transfer studies using human sera from the Phase 1 study. Safety data collection and immunogenicity will continue to be assessed until Month 12.


Recruitment information / eligibility

Status Completed
Enrollment 750
Est. completion date February 15, 2024
Est. primary completion date February 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: 1. From the 12th birthday to the last day before the 18th birthday on the Day of screening; 2. able to provide informed consent as well as written informed consent by the subject's legal representative ; 3. generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests; 4. seropositive for previous CHIKV exposure (i.e. IgM+/IgG+ or IgM-/IgG+) or seronegative (i.e. IgM-/IgG-) as screened by CHIKV-specific ELISA. 5. for women of childbearing potential: 1. negative serum or urine pregnancy test at screening. 2. practiced an adequate method of contraception during 30 days before screening 3. agrees to employ adequate birth control measures for the first three months post-vaccination (i.e. until Day 85). Exclusion Criteria: 1. CHIKV infection in the past, including suspected CHIKV infection; is taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or has participated in a clinical study involving an investigational CHIKV vaccine; 2. acute or recent infection; 3. tests positive for human immunodeficiency virus (HIV) human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV); 4. live virus vaccine within 28 days or inactivated vaccine within 14 days prior to vaccination in this study or plans to receive a vaccine within 28 days or 14 days after vaccination, respectively; 5. abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator which pose a risk for participation in the study; 6. medical history of or currently has acute or progressive, unstable or uncontrolled clinical conditions that pose a risk for participation in the study; 7. history of immune-mediated or clinically relevant arthritis / arthralgia; 8. history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the subject may be enrolled; 9. known or suspected defect of the immune system, such as subjects with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to vaccination; 10. history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications); 11. with clinical conditions representing a contraindication to intramuscular vaccination and blood draws; 12. pregnant or lactating at the time of enrollment; 13. donation of blood, blood fractions or plasma within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or plans to donate blood or use blood products until Day 180 of the study; 14. rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating; 15. known or suspected problem with alcohol or drug abuse as determined by the Investigator; 16. any condition that, in the opinion of the Investigator, may compromise the subjects well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study; 17. committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities); 18. participation in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study; 19. member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Active
Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
Placebo
Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo

Locations

Country Name City State
Brazil Centro de Pesquisas Clínicas Universidade Federal Sergipe Aracaju Sergipe
Brazil Centro de Pesquisa e Desenvolvimento de Fármacos (CPDF) - Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas Belo Horizonte Minas Gerais
Brazil CECOR - Centro Oncológico de Roraima Boa Vista Acre
Brazil Centro de Pesquisa Clínica da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS Campo Grande
Brazil Núcleo de Medicina Tropical - Universidade Federal do Ceará Fortaleza Ceará
Brazil Fundação de Medicina Tropical Dr. Heitor Vieira Dourado Manaus Amazonas
Brazil Real Hospital Português de Beneficência em Pernambuco Recife Pernambuco
Brazil Associação Obras Sociais Irmã Dulce / Centro de Pesquisa Clínica - CPEC Salvador Bahia
Brazil Faculdade de Medicina de São José do Rio Preto - FAMERP São José Do Rio Preto São Paulo
Brazil Centro de Estudos do Instituto de Infectologia Emílio Ribas São Paulo

Sponsors (2)

Lead Sponsor Collaborator
Butantan Institute Valneva Austria GmbH

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroprotection Proportion of subjects with a seroprotective CHIKV antibody level determined by µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects 28 days post-vaccination. up to Day 29 after single vaccination
Secondary Immunogenicity Immune response as measured by CHIKV-specific neutralizing antibody titers determined by µPRNT assay until Day 8, Day 85, Day 180, and Month 12 after vaccination
Secondary Seroprotection up to 1 year Proportion of subjects with seroprotective CHIKV antibody levels as determined by µPRNT Month 12. until Day 8, Day 29, Day 85, Day 180, and Month 12 after vaccination
Secondary Seroconversion up to 1 year Proportion of subjects with seroconversion as compared to baseline at Day 29, Month 6 and Month 12 as determined by µPRNT assay 12 months after vaccination
Secondary Fold Increase in neutralizing antibodies Fold increase of CHIKV-specific neutralizing antibody titers determined by µPRNT assay at Days 8, 29, 85, 180 and at Month 12 post-vaccination as compared to baseline 12 months after vaccination
Secondary Proportion of increase of neutralizing antibodies Proportion of subjects reaching an at least 4-fold, 8-fold, 16-fold or 64-fold increase in CHIKV-specific neutralizing antibody titer compared to baseline as measured by µPRNT assay 12 months after vaccination
Secondary Immunogenicity per baseline serostatus Antibody titers, seroprotection and fold increases for CHIKV-specific neutralizing antibodies, determined by µPRNT assay at Days 1, 8, 29, 85, 180, and Month 12 post-vaccination stratified by baseline serostatus 12 months after vaccination
Secondary Unsolicited adverse events Frequency and severity of unsolicited AEs until Day 29 and Month 6 post-vaccination 6 months after vaccination
Secondary Solicited adverse reactions Frequency and severity of solicited injection site and systemic reactions within ten days post-vaccination 10 days after vaccination
Secondary Frequency of adverse event of special interest Frequency and severity of any Adverse Event of Special Interest until 12 month after vaccination
Secondary Viremia of vaccine strain Frequency of viremia of vaccine strain detected on Days 1 and 8 (and Day 29, if applicable) after vaccination 29 days after vaccination
Secondary Frequency of Serious Adverse Event Frequency and relatedness of any Serious Adverse Event (SAE) during the entire study period until 12 month after vaccination
See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT04440774 - Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico. Phase 1
Completed NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A
Active, not recruiting NCT04343521 - Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Phase 3
Completed NCT03992872 - Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Phase 2
Completed NCT03382964 - Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Phase 1
Completed NCT02831699 - The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT06257810 - Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa Phase 4
Suspended NCT05218304 - Baromètre Santé Adulte 2021-2022 N/A
Recruiting NCT04615364 - Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Not yet recruiting NCT04672577 - Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
Completed NCT04434846 - Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Recruiting NCT04838574 - Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Recruiting NCT04619823 - Virological and Immunological Determinants of Arbovirus Infection in New Caledonia N/A
Completed NCT03101111 - Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Phase 2
Completed NCT02463968 - Chikungunya Arthritis in the Americas N/A
Active, not recruiting NCT04566484 - Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia Phase 2/Phase 3
Completed NCT04603131 - Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine Phase 1